119 related articles for article (PubMed ID: 38363238)
21. Stereotactic Hypofractionated Accurate Radiotherapy of the Prostate (SHARP), 36.25 Gy in Five Fractions for Localized Disease: A Case Series Results from King Faisal Specialist Hospital, Saudi Arabia.
Hegazy MW; Mahmood R
Gulf J Oncolog; 2016 May; 1(21):12-6. PubMed ID: 27250882
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review.
Foerster R; Zwahlen DR; Buchali A; Tang H; Schroeder C; Windisch P; Vu E; Akbaba S; Bostel T; Sprave T; Zamboglou C; Zilli T; Stelmes JJ; Telkhade T; Murthy V
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33673077
[TBL] [Abstract][Full Text] [Related]
23. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
[TBL] [Abstract][Full Text] [Related]
24. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
[TBL] [Abstract][Full Text] [Related]
25. Increased toxicities associated with dose escalation of stereotactic body radiation therapy in prostate cancer: results from a phase I/II study.
Hirata T; Suzuki O; Otani K; Miyake A; Tamari K; Seo Y; Isohashi F; Kai N; Hatano K; Fujita K; Uemura M; Imamura R; Tamenaga S; Yoshino Y; Fumimoto Y; Yoshioka Y; Nonomura N; Ogawa K
Acta Oncol; 2023 May; 62(5):488-494. PubMed ID: 37203203
[TBL] [Abstract][Full Text] [Related]
26. ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I/II trial.
Zilli T; Franzese C; Guckenberger M; Giaj-Levra N; Mach N; Koutsouvelis N; Achard V; Mcdonald A; Alongi F; Scorsetti M; Constantin G; Bertaut A; Miralbell R
Radiother Oncol; 2024 May; 194():110181. PubMed ID: 38403022
[TBL] [Abstract][Full Text] [Related]
27. Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity.
Ugurluer G; Atalar B; Zoto Mustafayev T; Gungor G; Aydin G; Sengoz M; Abacioglu U; Tuna MB; Kural AR; Ozyar E
Br J Radiol; 2021 Jan; 94(1117):20200696. PubMed ID: 33095670
[TBL] [Abstract][Full Text] [Related]
28. Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR).
Kim YJ; Ahn H; Kim CS; Kim YS
Radiat Oncol; 2020 Oct; 15(1):234. PubMed ID: 33032643
[TBL] [Abstract][Full Text] [Related]
29. A Prospective Study of Stereotactic Body Radiotherapy (SBRT) with Concomitant Whole-Pelvic Radiotherapy (WPRT) for High-Risk Localized Prostate Cancer Patients Using 1.5 Tesla Magnetic Resonance Guidance: The Preliminary Clinical Outcome.
Poon DMC; Yuan J; Yang B; Wong OL; Chiu ST; Chiu G; Cheung KY; Yu SK; Yung RWH
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884553
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic focal radiotherapy as an alternative treatment for low-risk prostate cancer: Results of a single-arm monocenter Phase-II trial.
Nguyen PV; Donneaux B; Louis C; Bodgal Z; Philippi S; Biver S; Frederick B; Harzé L; Lasar Y; Vogin G; Nickers P
Front Oncol; 2023; 13():1143716. PubMed ID: 37091187
[TBL] [Abstract][Full Text] [Related]
31. Dosimetric Predictors of Toxicity after Prostate Stereotactic Body Radiotherapy: A Single-Institutional Experience of 145 Patients.
Fujii K; Nakano M; Kawakami S; Tanaka Y; Kainuma T; Tsumura H; Tabata KI; Satoh T; Iwamura M; Ishiyama H
Curr Oncol; 2023 May; 30(5):5062-5071. PubMed ID: 37232841
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
Kim HJ; Phak JH; Kim WC
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e342-e347. PubMed ID: 26846353
[TBL] [Abstract][Full Text] [Related]
33. A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer.
Kawakami S; Tsumura H; Satoh T; Tabata K; Sekiguchi A; Kainuma T; Nakano M; Iwamura M; Ishiyama H
Radiat Oncol; 2022 Apr; 17(1):67. PubMed ID: 35379264
[TBL] [Abstract][Full Text] [Related]
34. A Phase 1 Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer.
Patel KR; Rydzewski NR; Schott E; Cooley-Zgela T; Ning H; Cheng J; Salerno K; Huang EP; Pinto PA; Lindenberg L; Mena E; Choyke P; Turkbey B; Citrin DE
Pract Radiat Oncol; 2023; 13(6):540-550. PubMed ID: 37442430
[TBL] [Abstract][Full Text] [Related]
35. Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer.
Chen L; Gannavarapu BS; Desai NB; Folkert MR; Dohopolski M; Gao A; Ahn C; Cadeddu J; Bagrodia A; Woldu S; Raj GV; Roehrborn C; Lotan Y; Timmerman RD; Garant A; Hannan R
Front Oncol; 2022; 12():779182. PubMed ID: 35265519
[TBL] [Abstract][Full Text] [Related]
36. A Multicenter Phase 2 Study of Ultrahypofractionated Stereotactic Boost After External Beam Radiotherapy in Intermediate-risk Prostate Carcinoma: A Very Long-term Analysis of the CKNO-PRO Trial.
Pasquier D; Nickers P; Peiffert D; Maingon P; Pommier P; Lacornerie T; Tresch E; Barthoulot M; Lartigau E
Eur Urol Open Sci; 2023 Aug; 54():80-87. PubMed ID: 37545850
[TBL] [Abstract][Full Text] [Related]
37. Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP).
Pepin A; Aghdam N; Shah S; Kataria S; Tsou H; Datta S; Danner M; Ayoob M; Yung T; Lei S; Gurka M; Collins BT; Krishnan P; Suy S; Hankins R; Lynch JH; Collins SP
Front Oncol; 2020; 10():555. PubMed ID: 32432033
[No Abstract] [Full Text] [Related]
38. Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial.
Morris BA; Holmes EE; Anger NJ; Cooley G; Schuster JM; Hurst N; Baschnagel AM; Bassetti MF; Blitzer GC; Chappell RJ; Bayliss RA; Morris ZS; Ritter MA; Floberg JM
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):613-623. PubMed ID: 37179035
[TBL] [Abstract][Full Text] [Related]
39. The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study.
Pasquier D; Lacornerie T; Supiot S; Pommier P; Quivrin M; Simon JM; Loos G; Meyer E; Calais G; Peiffert D; Vandendorpe B; Aymes E; Leguillette C; Brihoum M; Nenan S; Cormier L; Le Deley MC; Lartigau EF
Eur Urol Oncol; 2023 Aug; 6(4):399-405. PubMed ID: 36754722
[TBL] [Abstract][Full Text] [Related]
40. Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer.
Kim S; Kong JH; Lee Y; Lee JY; Kang TW; Kong TH; Kim MH; You SH
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012817. PubMed ID: 36884035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
